This Phase 1 clinical trial is designed to evaluate the safety and immune response of two experimental HIV vaccines, BG505 GT1.1 and 426c.Mod.Core-C4b, in HIV-negative adults. Using a prime-boost approach, the trial will assess these immunogens when combined with the 3M-052-AF and Alum adjuvants to understand their potential to generate effective antibody responses against HIV.
Safety and Tolerability: Determine the safety profile and tolerability of BG505 GT1.1 and 426c.Mod.Core-C4b in combination with 3M-052-AF and Alum adjuvants.
Antibody Response: Measure the quality and quantity of antibodies produced, focusing on Env-specific binding and neutralizing antibodies to assess potential protective effects.
This randomized, controlled, double-blind trial takes place across multiple research sites, ensuring robust data collection. Participants will receive the vaccine candidates intramuscularly, following a precise dosing schedule as per the study protocol.
This study represents a promising step toward developing an effective HIV vaccine by advancing our understanding of immune responses and antibody generation.
Disclaimer: This website is made possible with the support of the American people through the United States Agency for International Development (USAID).
The contents are the sole responsibility of the BRILLIANT consortium and do not necessarily reflect the views of USAID or the United States Government.
